Ligand Pharmaceuticals Hits New 52-Week High of $186.40

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 186.40 on October 8, 2025. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,250 million.
Over the past year, Ligand Pharmaceuticals has demonstrated impressive growth, with a remarkable 131.98% increase in its stock price, significantly outperforming the S&P 500, which recorded a gain of 17.88% during the same period. Despite being a loss-making company, Ligand's price-to-book ratio stands at 3.92, indicating a valuation that reflects investor sentiment and market positioning.

The company's financial metrics reveal a debt-to-equity ratio of -0.29 and a return on equity of -5.83%, highlighting its current financial structure. With no dividend yield reported, Ligand Pharmaceuticals continues to focus on its core operations within the competitive landscape of the biotechnology industry. The recent price movement marks a notable point in the company's trajectory, reflecting its ongoing developments and market dynamics.